Top

Published in:

01-11-2015 | Research Article

Mitochondrial genome instability in colorectal adenoma and adenocarcinoma

Authors: Luiza F. de Araujo, Aline S. Fonseca, Bruna R Muys, Jessica R. Plaça, Rafaela B. L. Bueno, Julio C. C. Lorenzi, Anemari R. D. Santos, Greice A. Molfetta, Dalila L. Zanette, Jorge E. S. Souza, Valeria Valente, Wilson A. Silva Jr

Published in: Tumor Biology | Issue 11/2015

Abstract

Mitochondrial dysfunction is regarded as a hallmark of cancer progression. In the current study, we evaluated mitochondrial genome instability and copy number in colorectal cancer using Next Generation Sequencing approach and qPCR, respectively. The results revealed higher levels of heteroplasmy and depletion of the relative mtDNA copy number in colorectal adenocarcinoma. Adenocarcinoma samples also presented an increased number of mutations in nuclear genes encoding proteins which functions are related with mitochondria fusion, fission and localization. Moreover, we found a set of mitochondrial and nuclear genes, which cooperate in the same mitochondrial function simultaneously mutated in adenocarcinoma. In summary, these results support an important role for mitochondrial function and genomic instability in colorectal tumorigenesis.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

INCA. Estimativa 2014—Incidência de Câncer no Brasil. Rio de Janeiro, RJ. 2014. Accessed 04/28/15.

Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B. Colorectal cancer. Lancet. 2010;375(9719):1030–47. doi:10.1016/S0140-6736(10)60353-4.CrossRefPubMed

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.CrossRefPubMed

Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107(19):8788–93. doi:10.1073/pnas.1003428107.CrossRefPubMedPubMedCentral

Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol. 2005;25(15):6391–403. doi:10.1128/MCB.25.15.6391-6403.2005.CrossRefPubMedPubMedCentral

Gaude E, Frezza C. Defects in mitochondrial metabolism and cancer. Cancer Metab. 2014;2:10. doi:10.1186/2049-3002-2-10.CrossRefPubMedPubMedCentral

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.CrossRefPubMed

Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9(6):425–34. doi:10.1016/j.ccr.2006.04.023.CrossRefPubMed

10.

Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 2015;21(1):81–94. doi:10.1016/j.cmet.2014.12.003.CrossRefPubMed

11.

Wallace DC. Structure and evolution of organelle genomes. Microbiol Rev. 1982;46(2):208–40.PubMedPubMedCentral

12.

Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290(5806):457–65.CrossRefPubMed

13.

Singh RK, Srivastava A, Kalaiarasan P, Manvati S, Chopra R, Bamezai RN. mtDNA germ line variation mediated ROS generates retrograde signaling and induces pro-cancerous metabolic features. Sci Rep. 2014;4:6571. doi:10.1038/srep06571.CrossRefPubMedPubMedCentral

14.

Ishikawa K, Hayashi J. A novel function of mtDNA: its involvement in metastasis. Ann N Y Acad Sci. 2010;1201:40–3. doi:10.1111/j.1749-6632.2010.05616.x.CrossRefPubMed

15.

Kaipparettu BA, Ma Y, Park JH, Lee TL, Zhang Y, Yotnda P, et al. Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways. PLoS One. 2013;8(5):e61747. doi:10.1371/journal.pone.0061747.CrossRefPubMedPubMedCentral

16.

He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature. 2010;464(7288):610–4. doi:10.1038/nature08802.CrossRefPubMedPubMedCentral

17.

Larman TC, DePalma SR, Hadjipanayis AG, Protopopov A, Zhang J, Gabriel SB, et al. Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A. 2012;109(35):14087–91. doi:10.1073/pnas.1211502109.CrossRefPubMedPubMedCentral

18.

Lee JH, Hwang I, Kang YN, Choi IJ, Kim DK. Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis. PLoS One. 2015;10(3):e0118612. doi:10.1371/journal.pone.0118612.CrossRefPubMedPubMedCentral

19.

Lim SW, Kim HR, Kim HY, Huh JW, Kim YJ, Shin JH, et al. High-frequency minisatellite instability of the mitochondrial genome in colorectal cancer tissue associated with clinicopathological values. Int J Cancer. 2012;131(6):1332–41. doi:10.1002/ijc.27375.CrossRefPubMed

20.

Ye K, Lu J, Ma F, Keinan A, Gu Z. Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals. Proc Natl Acad Sci U S A. 2014;111(29):10654–9. doi:10.1073/pnas.1403521111.

21.

Taylor RW, Taylor GA, Durham SE, Turnbull DM. The determination of complete human mitochondrial DNA sequences in single cells: implications for the study of somatic mitochondrial DNA point mutations. Nucl Acids Res. 2001;29(15):E74–4.

22.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9. doi:10.1038/nmeth0410-248.CrossRefPubMedPubMedCentral

23.

Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, et al. Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics. 2009;25(21):2744–50. doi:10.1093/bioinformatics/btp528.CrossRefPubMedPubMedCentral

24.

Untergasser A, Cutcutache I, Koressaar T, Ye J, Remme M. Primer3—new capabilities and interfaces. Nucleic Acids Res. 2012;40(15):e115. doi:10.1093/nar/gks596.CrossRefPubMedPubMedCentral

25.

Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23(10):1289–91. doi:10.1093/bioinformatics/btm091.CrossRefPubMed

26.

Venegas V, Wang J, Dimmock D, Wong LJ. Real-time quantitative PCR analysis of mitochondrial DNA content. Current protocols in human genetics / editorial board, Jonathan L Haines [et al]. 2011;Chapter 19:Unit 19 7. doi:10.1002/0471142905.hg1907s68.

27.

Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60. doi:10.1093/bioinformatics/btp324.CrossRefPubMedPubMedCentral

28.

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–9. doi:10.1093/bioinformatics/btp352.CrossRefPubMedPubMedCentral

29.

DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8. doi:10.1038/ng.806.CrossRefPubMedPubMedCentral

30.

Gasparre G, Porcelli AM, Lenaz G, Romeo G. Relevance of mitochondrial genetics and metabolism in cancer development. Cold Spring Harb Perspect Biol. 2013;5(2). doi:10.1101/cshperspect.a011411.

31.

Iommarini L, Kurelac I, Capristo M, Calvaruso MA, Giorgio V, Bergamini C, et al. Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. Hum Mol Genet. 2014;23(6):1453–66. doi:10.1093/hmg/ddt533.CrossRefPubMed

32.

Tan AS, Baty JW, Berridge MV. The role of mitochondrial electron transport in tumorigenesis and metastasis. Biochim Biophys Acta. 2014;1840(4):1454–63. doi:10.1016/j.bbagen.2013.10.016.CrossRefPubMed

33.

Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998;20(3):291–3. doi:10.1038/3108.CrossRefPubMed

34.

Blok MJ, Spruijt L, de Coo IF, Schoonderwoerd K, Hendrickx A, Smeets HJ. Mutations in the ND5 subunit of complex I of the mitochondrial DNA are a frequent cause of oxidative phosphorylation disease. J Med Genet. 2007;44(4):e74. doi:10.1136/jmg.2006.045716.CrossRefPubMedPubMedCentral

35.

Naini AB, Lu J, Kaufmann P, Bernstein RA, Mancuso M, Bonilla E, et al. Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF. Arch Neurol. 2005;62(3):473–6. doi:10.1001/archneur.62.3.473.CrossRefPubMed

36.

Danovi D, Cremona CA, Machado-da-Silva G, Basu S, Noon LA, Parrinello S, et al. A genetic screen for anchorage-independent proliferation in mammalian cells identifies a membrane-bound neuregulin. PLoS One. 2010;5(7):e11774. doi:10.1371/journal.pone.0011774.CrossRefPubMedPubMedCentral

37.

Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, et al. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A. 2007;104(18):7540–5. doi:10.1073/pnas.0610818104.CrossRefPubMedPubMedCentral

38.

Zhang C, Huang VH, Simon M, Sharma LK, Fan W, Haas R, et al. Heteroplasmic mutations of the mitochondrial genome cause paradoxical effects on mitochondrial functions. FASEB J. 2012;26(12):4914–24. doi:10.1096/fj.12-206532.CrossRefPubMed

39.

Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, et al. The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum Mol Genet. 2010;19(6):1019–32. doi:10.1093/hmg/ddp566.CrossRefPubMed

40.

Koshikawa N, Hayashi J, Nakagawara A, Takenaga K. Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J Biol Chem. 2009;284(48):33185–94. doi:10.1074/jbc.M109.054221.CrossRefPubMedPubMedCentral

41.

Kurelac I, MacKay A, Lambros MB, Di Cesare E, Cenacchi G, Ceccarelli C. Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. Hum Mol Genet. 2013;22(2):226–38. doi:10.1093/hmg/dds422.CrossRefPubMed

42.

Levinger L, Morl M, Florentz C. Mitochondrial tRNA 3′ end metabolism and human disease. Nucleic Acids Res. 2004;32(18):5430–41. doi:10.1093/nar/gkh884.

43.

Coenen MJ, Antonicka H, Ugalde C, Sasarman F, Rossi R, Heister JG, et al. Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. N Engl J Med. 2004;351(20):2080–6. doi:10.1056/NEJMoa041878.CrossRefPubMed

44.

Smeitink JA, Elpeleg O, Zntonicka H, Diepstra H, Saada A, Smits P, et al. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am J Hum Genet. 2006;79(5):869–77. doi:10.1086/508434.CrossRefPubMedPubMedCentral

45.

Desai SP, Bhatia SN, Toner M, Irimia D. Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys J. 2013;104(9):2077–88. doi:10.1016/j.bpj.2013.03.025.CrossRefPubMedPubMedCentral

46.

Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013;32(40):4814–24. doi:10.1038/onc.2012.494.CrossRefPubMed

47.

Yu M, Shi Y, Wei X, Yang Y, Zang F, Niu R. Mitochondrial DNA depletion promotes impaired oxidative status and adaptive resistance to apoptosis in T47D breast cancer cells. Eur J Cancer Prev. 2009;18(6):445–57. doi:10.1097/CEJ.0b013e32832f9bd6.CrossRefPubMed

48.

Guha M, Avadhani NG. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion. 2013;13(6):577–91. doi:10.1016/j.mito.2013.08.007.CrossRefPubMed

49.

Yu M. Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci. 2011;89(3-4):65–71. doi:10.1016/j.lfs.2011.05.010.CrossRefPubMed

50.

Cui H, Huang P, Wang Z, Zhang Y, Zhang Z, Xu W, et al. Association of decreased mitochondrial DNA content with the progression of colorectal cancer. BMC Cancer. 2013;13:110. doi:10.1186/1471-2407-13-110.CrossRefPubMedPubMedCentral

51.

Kirches E. Mitochondrial and nuclear genes of mitochondrial components in cancer. Curr Genom. 2009;10(4):281–93. doi:10.2174/138920209788488517.CrossRef

52.

Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, et al. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res. 2011;21(1):12–20. doi:10.1101/gr.108696.CrossRefPubMedPubMedCentral

53.

Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639–45. doi:10.1101/gr.092759.109.CrossRefPubMedPubMedCentral

Title: Mitochondrial genome instability in colorectal adenoma and adenocarcinoma
Authors: Luiza F. de Araujo
Aline S. Fonseca
Bruna R Muys
Jessica R. Plaça
Rafaela B. L. Bueno
Julio C. C. Lorenzi
Anemari R. D. Santos
Greice A. Molfetta
Dalila L. Zanette
Jorge E. S. Souza
Valeria Valente
Wilson A. Silva Jr
Publication date: 01-11-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 11/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3640-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2015

Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair

Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers

miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2

Further considerations on hepatic lesion discrimination using diffusion MR imaging

Andrographolide radiosensitizes human ovarian cancer SKOV3 xenografts due to an enhanced apoptosis and autophagy

Postoperative dynamic changes in the concentration of CK19-2G2 in lung cancer patients and the clinical value of this marker

Keynote webinar | Spotlight on antibody–drug conjugates in cancer